Recursion Pharmaceuticals, INC 8-K filings

Recursion Pharmaceuticals released positive top-line results from its SYCAMORE trial and announced a proposed acquisition of Exscientia, including key financial details.

Recursion Pharmaceuticals has obtained an irrevocable undertaking from Evotec SE, further solidifying support for its acquisition of Exscientia.

Recursion and Exscientia have agreed to merge, combining their AI-driven drug discovery platforms and pipelines to accelerate the development of new medicines.

Recursion Pharmaceuticals announced that Genentech has exercised its option for the first Neuroscience Phenomap, triggering a $30 million payment to Recursion.

Recursion Pharmaceuticals has announced a public offering of 30,769,230 shares of its Class A common stock at a price of $6.50 per share, aiming to raise approximately $200 million.

Recursion Pharmaceuticals provided updates on its clinical pipeline, including seven expected clinical trial readouts within approximately 18 months, and highlighted advancements in its partnerships and platform technology at its Download Day investor meeting.

Recursion Pharmaceuticals held its 2024 annual meeting of stockholders on June 3, 2024, where shareholders voted on the election of directors and executive compensation.

Recursion Pharmaceuticals has appointed Robert Hershberg as the new Chair of the Board, succeeding R. Martin Chavez, effective at the 2024 Annual Meeting of Stockholders.

Recursion Pharmaceuticals reported its Q1 2024 financial results, highlighted by progress in clinical trials, platform expansion, and strategic partnerships.

Recursion Pharmaceuticals has appointed Najat Khan as Chief Research and Development Officer and Chief Commercial Officer, while also adding her to the Board of Directors, effective April 16, 2024.

Recursion Pharmaceuticals announced its fourth quarter and full year 2023 financial results, highlighting progress in its clinical programs and platform advancements using AI and machine learning.

Recursion Pharmaceuticals has announced a transition in its executive leadership, with Dr. Shafique Virani moving to a Senior Strategic Advisor role and Matthew Kinn assuming the position of Chief Business Officer.

Recursion Pharmaceuticals amended its bylaws on January 25, 2024, to enhance procedural mechanics, align with new universal proxy rules, and conform to recent changes in Delaware law.